# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Yaron Werber upgrades Ascendis Pharma (NASDAQ:ASND) from Hold to Buy and raises the price target from $156 ...
The data showed that patients treated for one year at the pivotal 100μg/kg/week dose demonstrated significant improvements in w...
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated...
Stifel analyst Alex Thompson initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Targe...
Morgan Stanley analyst Vikram Purohit maintains Ascendis Pharma (NASDAQ:ASND) with a Equal-Weight and raises the price targe...